2023 World Conference on Lung Cancer (Posters)-P1.23. Clinical Impact of Clonal Hematopoiesis in Patients with Advanced Non-small Cell Lung Cancer: Results of the CHIC Study

P1.23. Clinical Impact of Clonal Hematopoiesis in Patients with Advanced Non-small Cell Lung Cancer: Results of the CHIC Study - PDF(Abstract)

Back to course

Pdf Summary

The study presented at WCLC 2023 aimed to explore the impact of clonal hematopoiesis (CH) in patients with advanced non-small cell lung cancer (aNSCLC). The retrospective analysis included 190 patients with aNSCLC who were part of the MATCH-R study at Gustave Roussy in France. CH was evaluated using a targeted NGS panel on DNA extracted from peripheral leukocytes. The results showed that 35% of the patients had at least one CH mutation, with the most common mutations found in epigenetic modifiers and DNA damage response genes. However, the presence of CH did not have a significant impact on overall survival (OS) in the patients. <br /><br />Variables associated with worse OS in the multivariate analysis were a ECOG performance status of 1, presence of liver metastases, number of lines of systemic anticancer therapy (SACT) received, and a high neutrophil-to-lymphocyte ratio. On the other hand, a better OS was associated with targeted therapy for a tumor molecular alteration and immunotherapy. <br /><br />Overall, the study found a relatively high incidence of CH in patients with aNSCLC, but no negative impact on OS. This suggests that CH may not be a significant prognostic factor in aNSCLC and other factors such as performance status, metastases, and previous treatments play a more significant role in determining survival outcomes.

Asset Subtitle

Marco Tagliamento

Meta Tag

Speaker Marco Tagliamento

Topic Pathology & Biomarkers: Liquid Based Biomarkers

Keywords

clonal hematopoiesis

advanced non-small cell lung cancer

retrospective analysis

MATCH-R study

NGS panel

epigenetic modifiers

DNA damage response genes

overall survival

targeted therapy

immunotherapy